₹103 per tablet. While this gives the company an edge as first-mover, much will depend on how the company will capitalise on this opportunity.In India, about 80-85% of covid-19 patients have mild to moderate levels of the disease.
In fact, the Drug Controller General of India (DCGI) granted Glenmark Pharmaceuticals the permission to manufacture and market favipiravir for “restricted emergency use" in mild to moderate cases.The revenue potential from the drug launch seems limited.
Glenmark could generate about ₹100-150 crore of revenues from the sales of Fabiflu, according to analysts. But this does not seem to quite justify the share price jump of about 40% intraday.